This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).
Therapeutic Indication
### Therapeutic indication **In the female:** Puregon is indicated for the treatment of female infertility in the following clinical situations: - anovulation (including polycystic ovarian syndrome, PCOS) in women who have been unresponsive to treatment with clomifene citrate; - controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs (e.g. in-vitro fertilisation / embryo transfer (IVF/ET), gamete intrafallopian transfer (GIFT) and intracytoplasmic sperm injection (ICSI)). **In the male:** - Deficient spermatogenesis due to hypogonadotrophic hypogonadism.
Therapeutic Area (MeSH)
ATC Code
G03GA06
ATC Item
follitropin beta
Pharmacotherapeutic Group
Sex hormones and modulators of the genital system
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| follitropin beta | N/A | 重组人促卵泡激素 |
EMA Name
Puregon
Medicine Name
Puregon
Aliases
N/ANo risk management plan link.
